Cryptococcal meningitis kills up to 500,000 people with AIDS in Africa each year. The current best treatment—two weeks of intravenous amphotericin B—is expensive, hard to give in rural hospitals, and causes serious side effects that require frequent blood tests. The cheap oral alternative, fluconazole, is far less effective at stopping the infection. This trial tests two simpler, shorter alternatives in 570 patients across Malawi and Zambia: a one-week course of amphotericin B, and a combination of high-dose fluconazole plus flucytosine taken as tablets. Both have shown in smaller studies that they kill the fungus faster than fluconazole alone, with fewer side effects than the standard two-week regimen. If either matches the survival rate of the current best treatment, it could transform how cryptococcal meningitis is managed across sub-Saharan Africa—replacing a difficult, resource-intensive hospital procedure with a treatment that is practical, affordable, and deliverable in basic clinics. The trial also compares costs, so funders and health ministries can make evidence-based decisions about which regimen to adopt.
View original technical description
Cryptococcal meningitis is one of the commonest causes of death in patients with AIDS and is associated with up to 500,000 deaths each year in Africa alone. A large proportion of patients die from the infection, in part because the current recommended treatment, amphotericin B for 2 weeks, is difficult to give in hospitals in the developing world, because it is relatively expensive and needs to be given intravenously and has side effects, often starting in the second week, meaning monitoring is needed with frequent blood tests. The alternative oral tablet treatment, fluconazole, that is available and cheap and currently commonly used, is much less effective. Therefore, based on a number of earlier small trials by the study team, we wish to test 2 new treatments, (1) Short, 1-week amphotericin B, and (2) Combination tablet treatment with high dose fluconazole plus another drug called flucytosine, that are as fast and effective in killing the infection as 2 weeks of amphotericin B. We will compare these new treatments with 2 weeks amphotericin B, in a larger, randomised trial that will enable us to see whether they are as good in preventing deaths from the infection. After 2 weeks of the study treatments, all patients will receive the usual follow on therapy with fluconazole, and will be started on drugs for the underlying HIV infection, as currently recommended, and followed up for 10 weeks. 570 patients (190 given each alternative treatment) will be studied. This is the minimum number needed to reliably compare the results of the treatments. The project has been developed with doctors in 3 centres in Malawi and Zambia where there are many cases and where alternative, affordable and practical treatments are urgently needed. Each centre has the laboratories needed, and experience in doing such trials. Both test treatments have been shown to be much more rapidly effective than fluconazole alone, and would have less side effects and be much more easily given in developing countries than 2 weeks amphotericin B. However, if 2 weeks amphotericin B was found to be the best treatment, then the costs required for its use could be justified. The costs as well as the effectiveness of the treatments will be compared to help decide which treatment to recommend in the future.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know